Circadian changes direction
Thursday, 12 June, 2008
Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.
Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.
The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
